This trial is active, not recruiting.

Condition asthma
Treatment minocycline
Phase phase 2
Sponsor State University of New York - Downstate Medical Center
Start date June 1996
End date October 2007
Trial size 20 participants
Trial identifier NCT00456677, Heikki31


Trial of effects of minocycline as "add-on" therapy to adults with asthma with a history of requiring at least one episode of oral steroid therapy to control the disease.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model crossover assignment
Masking double-blind
Primary purpose treatment

Primary Outcomes

Decrease in oral steroid therapy requirements.
time frame:

Secondary Outcomes

improvement in symptoms scores
time frame:
improvement in spirometric outcomes
time frame:
improvement in morning and evening peak flow
time frame:
decrease in rescue inhaler usage
time frame:

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: - Adult asthmatics - History of or current use of oral steroids to control symptoms Exclusion Criteria: - Pregnant women

Additional Information

Official title Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma
Principal investigator Rauno Joks, MD
Description This is a double-blind, placebo-controlled crossover study of adult asthmatics given minocycline 150 mg po BID or placebo as add-on therapy for eight weeks each. Each eight week arm is separated by a four week wash-out. Spirometry is performed at the baseline and end of each arm. Daily symptoms scores, peak flow rates, and oral steroid requirements are recorded. A standardized asthma quality of life symptoms assessment is made every four weeks (AQLQ, Juniper).
Trial information was received from ClinicalTrials.gov and was last updated in April 2007.
Information provided to ClinicalTrials.gov by State University of New York - Downstate Medical Center.